Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ENDONOVO THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2014
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Revenue
0.02
0.02
0
0.08
0.31
0.17
0.07
0.14
Cost of revenue
0.01
0.02
0
0.01
0.09
0.07
0.01
0.01
Gross profit
0.01
0.01
0
0.07
0.22
0.1
0.06
0.13
Research and development
0
0.12
0.27
0.15
0
0
Operating expenses
2.44
2.2
2.57
5.41
4.6
4.23
4.03
3.01
2.28
3.39
Operating income
-2.43
-2.19
-2.56
-5.41
-4.6
-4.16
-3.81
-2.91
-2.23
-3.26
Interest expense
0.02
2.08
0.94
Other non-operating income
1.23
-4.2
0.1
-6.21
-2.28
-13.5
2.52
-0.88
-15.2
Pre-tax income
-2.89
-0.96
-6.77
-5.32
-10.8
-6.44
-17.3
-0.4
-3.1
-18.5
Income tax
0
0
0
Net income
-2.89
-0.96
-6.77
-5.32
-10.8
-6.44
-17.3
-0.4
-3.1
-18.5
EBITDA
-2.42
-2.18
-2.55
-5.4
-4.59
-3.51
-3.16
-2.26
-1.58
-2.62
EPS, basic
-3,516.00
-26.64
-62.16
-44.40
-35.52
-17.76
-24.83
-0.03
-0.05
-0.13
EPS, diluted
-3,516.00
-26.64
-62.16
-44.40
-35.52
-17.76
-24.83
-0.03
-0.05
-0.13
Shares, basic (weighted)
0
0.03
0.11
0.13
0.27
0.36
0.7
12.2
59.8
139
Shares, diluted (weighted)
0
0.03
0.11
0.13
0.27
0.36
0.7
12.2
59.8
139
Balance sheet
FY2014
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Cash and equivalents
0
0
0.04
0.06
0.09
0.38
0.02
0.01
0.09
0
Receivables
0
0.02
0
0
Other current assets
0
0.34
0.25
0.02
0.02
0.03
0.01
0.02
Total current assets
0
0
0.38
0.3
0.11
0.38
0.06
0.05
0.09
0.02
Property, plant and equipment
0.06
0.04
0.03
0.02
0
0.01
0.01
0
Goodwill
0.2
Intangible assets
0.01
4.5
3.85
3.21
2.56
1.91
1.27
Total assets
0.07
0.05
0.41
0.32
4.61
4.24
3.27
2.61
2.01
1.28
Accounts payable
3.29
3.17
3.99
4.73
0.14
0.16
0.6
0.7
0.66
0.88
Accrued liabilities
0.49
0.79
Short-term debt
0.01
0.01
0.01
0
Total current liabilities
4.01
4.55
9.49
8.72
13.4
15.5
23.6
16.8
17.7
33.4
Long-term debt
0.04
0.03
0.03
0.02
0.02
0.03
0.04
Other non-current liabilities
0.08
0.08
Total liabilities
4.21
4.74
9.69
8.88
14.2
15.6
23.8
17
17.8
33.5
Total debt
1.57
0.03
3.19
7.36
8.16
6.87
6.84
7.26
7.15
Paid-in capital
1.19
1.59
3.77
9.8
19.6
24.2
32.4
39
40.7
42.9
Retained earnings
-5.33
-6.29
-13.1
-18.4
-29.2
-35.6
-52.9
-53.3
-56.4
-75.1
Shareholders' equity
-4.13
-4.69
-9.28
-8.56
-9.55
-11.4
-20.5
-14.4
-15.8
-32.2
Total equity
-4.13
-4.69
-9.28
-8.56
-9.55
-11.4
-20.5
-14.4
-15.8
-32.2
Total liabilities and equity
0.07
0.05
0.41
0.32
4.61
4.24
3.27
2.61
2.01
1.28
Shares outstanding
0
0.09
0.12
0.15
0.36
0.43
1.19
24.5
74.5
213
Cash flow statement
FY2014
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Net income
-2.89
-0.96
-6.77
-5.32
-10.8
-6.44
-17.3
-0.4
-3.1
-18.5
Depreciation and amortization
0.01
0.02
0.01
0.02
0.01
0.65
0.65
0.65
0.65
0.65
Stock-based compensation
0.03
0.06
0
0.05
Change in receivables
-0
-0
-0.02
0.02
-0
Change in payables
1.8
1.38
0.9
0.53
-0.11
0.06
0.44
0.09
-0.04
0.27
Cash from operations
-0.26
-0.91
-1.02
-2.46
-2.99
-2.88
-2.54
-0.74
-0.99
-0.68
Capital expenditures
0
-0
-0.01
-0
Acquisitions
0
Cash from investing
0
0
-0
-3
-0.01
-0
Debt issued
1.92
0.7
1.1
0.6
Debt repaid
-0.56
-0.11
-0.02
Stock issued
0
0.14
1.24
1.29
0.09
0.17
0.1
0.13
0.14
Cash from financing
0.26
0.91
1.06
2.48
6.02
3.18
2.18
0.74
1.06
0.59
Net change in cash
0
-0
0.04
0.01
0.03
0.29
-0.36
-0.01
0.07
-0.09
Free cash flow
-0.91
-1.02
-2.89
-2.54
Interest paid
0
0
0.01
0.03
0.03
0.25
0.02
0.03
Income taxes paid
0
0
0
0.06
0.12
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2023; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
96.2%
Gross profit / revenue.
Operating margin
-1,023.0%
Operating income / revenue.
Pre-tax margin
-1,722.0%
Pre-tax income / revenue.
Net margin
-1,722.0%
Net income / revenue.
Operating cash flow margin
-246.3%
Cash from operations / revenue.
Return on assets (ROA)
-539.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
85.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-24.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
115.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-16.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-36.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-26.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-22.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
132.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
484.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
248.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.00x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Debt / assets
868.5%
Total debt / total assets.
Liabilities / assets
2,915.0%
Total liabilities / total assets.
Net debt
$7.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.07
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
What was ENDONOVO THERAPEUTICS, INC.'s revenue in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. reported revenue of $135.4K for fiscal 2022, 85.2% higher than the year before.
Was ENDONOVO THERAPEUTICS, INC. profitable in fiscal 2022?
No. It reported a net loss of $18.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.